BioCity Collaborated with AstraZeneca to Evaluate BC3402 + Imfinzi (durvalumab) for Advanced Hepatocellular Carcinoma in China
Shots:
- The companies collaborated to evaluate the safety and efficacy of BioCity's BC3402 + AstraZeneca's Imfinzi (anti-PD-L1 mAb) in a P-Ib/II clinical study for the treatment of advanced HCC in China. The study will be conducted at Zhongshan Hospital with Prof. Jia Fan
- The therapy also showed synergistic anti-cancer activity with mAbs targeting PD-1 and CTLA-4 for liver cancer. Additionally, the company has 6 oncology assets which are currently in P-I development
- BC3402, a mAb targeting the T cell immunoglobulin and mucin domain-containing protein. The therapy has a higher binding affinity over other anti-TIM-3 mAbs in development
Ref: PR Newswire | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
